Metastatic Gastroesophageal Junction Adenocarcinoma (DBCOND0076921)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Tipiracil	A thymidine phosphorylase inhibitor used as an adjunct treatment of adult patients with certain types of gastric or colorectal malignancies.	Thymidine phosphorylasetarget Solute carrier family 22 member 2transporter Multidrug and toxin extrusion protein 1transporter
Trastuzumab	A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.	Receptor tyrosine-protein kinase erbB-2target
Trifluridine	A nucleoside metabolic inhibitor used to treat keratoconjunctivitis and epithelial keratitis caused by simplex virus, and as a part of chemotherapy for certain types of metastatic gastrointestinal cancers.	Thymidylate synthasetarget DNAtarget Thymidine kinase, cytosolicenzyme Thymidine phosphorylaseenzyme Solute carrier family 22 member 6transporter Sodium/nucleoside cotransporter 1transporter Equilibrative nucleoside transporter 1transporter Equilibrative nucleoside transporter 2transporter Albumincarrier Thymidylate synthasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06203600	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	Lexatumumab Nivolumab Paclitaxel Ramucirumab	treatment	2 / 3	recruiting
NCT06251973	A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer	Balstilimab Botensilimab Paclitaxel Ramucirumab	treatment	2	recruiting
NCT06364410	Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	Azenosertib Trastuzumab deruxtecan	treatment	1	recruiting
NCT04535401	Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	Calcium Camptothecin Elimusertib Fluorouracil Irinotecan Leucovorin Levoleucovorin	treatment	1	active_not_recruiting
NCT04704661	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Ceralasertib Trastuzumab deruxtecan	treatment	1	recruiting
NCT04511039	Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	TAS-102 Talazoparib Thymidine Tipiracil Trifluridine	treatment	1	recruiting
NCT05041153	Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	Lenvatinib Pembrolizumab	treatment	0	recruiting
NCT04840264	Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction	Docetaxel Fluorouracil Oxaliplatin	treatment	2	recruiting
NCT04221893	Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers	No drug interventions	treatment	Not Available	recruiting
NCT03008278	Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery	Lexatumumab Olaparib Ramucirumab	treatment	1 / 2	active_not_recruiting
NCT03641313	Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	Berzosertib Irinotecan	treatment	2	active_not_recruiting
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Pembrolizumab Sonidegib	treatment	1	recruiting
NCT03739801	MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Irinotecan Ramucirumab	treatment	1 / 2	withdrawn
NCT04921904	Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	Abemaciclib Ramucirumab	treatment	1 / 2	unknown_status
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT05677490	mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma	Fluorouracil Irinotecan Leucovorin Nivolumab Oxaliplatin	treatment	3	recruiting
NCT03337087	Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer	Calcium Fluorouracil Irinotecan Leucovorin Levoleucovorin Rucaparib	treatment	1 / 2	active_not_recruiting
NCT05555251	BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	Trastuzumab	treatment	1 / 2	active_not_recruiting
NCT03395847	Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma	Pembrolizumab	treatment	0	completed
NCT01142388	Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer	Cixutumumab Paclitaxel	treatment	2	active_not_recruiting
NCT04460937	Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers	Adavosertib	treatment	1	active_not_recruiting
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting
NCT03918499	IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer	Cyclophosphamide IRX-2 Pembrolizumab	treatment	1 / 2	completed
NCT04781686	Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer	Camrelizumab Docetaxel Rivoceranib	treatment	2	recruiting
NCT06329973	Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer	Fruquintinib Sintilimab	treatment	1 / 2	recruiting
NCT04220827	Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer	Paclitaxel	treatment	1	active_not_recruiting
NCT04660760	Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	Lexatumumab Paclitaxel Ramucirumab TAS-102 Tipiracil Trifluridine	treatment	2	recruiting
NCT05651594	Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	Fluorouracil Leucovorin Oxaliplatin Pembrolizumab Propranolol	treatment	2	recruiting
NCT05342389	Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer	Camrelizumab Rivoceranib	treatment	2	unknown_status
NCT02391038	MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	Indusatumab vedotin	treatment	1	terminated